GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GemPharmatech Co Ltd (SHSE:688046) » Definitions » Debt-to-Revenue

GemPharmatech Co (SHSE:688046) Debt-to-Revenue : 0.32 (As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is GemPharmatech Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

GemPharmatech Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥153.9 Mil. GemPharmatech Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥61.9 Mil. GemPharmatech Co's annualized Revenue for the quarter that ended in Mar. 2025 was ¥683.4 Mil. GemPharmatech Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 was 0.32.


GemPharmatech Co Debt-to-Revenue Historical Data

The historical data trend for GemPharmatech Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GemPharmatech Co Debt-to-Revenue Chart

GemPharmatech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial 0.02 0.06 0.04 0.20 0.19

GemPharmatech Co Quarterly Data
Dec18 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.21 0.17 0.19 0.32

Competitive Comparison of GemPharmatech Co's Debt-to-Revenue

For the Biotechnology subindustry, GemPharmatech Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GemPharmatech Co's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GemPharmatech Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where GemPharmatech Co's Debt-to-Revenue falls into.


;
;

GemPharmatech Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

GemPharmatech Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(96.86 + 35.622) / 686.837
=0.19

GemPharmatech Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(153.949 + 61.894) / 683.424
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2025) Revenue data.


GemPharmatech Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of GemPharmatech Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


GemPharmatech Co Business Description

Traded in Other Exchanges
N/A
Address
No. 12, Xuefu Road, Jiangbei New District, Jiangsu Province, Nanjing, CHN, 210032
GemPharmatech Co Ltd is a provider of?genetically engineered mouse?models?and services to global preclinical research and development communities. It specializes in developing animal models using cutting edge gene-editing technologies with a large collection of?cKO/KO (conditional knockout/knockout) mice, humanized mice, immunodeficient mice, and germ-free mice.

GemPharmatech Co Headlines

No Headlines